Related references
Note: Only part of the references are listed.Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma
Bimal Bhindi et al.
EUROPEAN UROLOGY (2020)
Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy
Andrew G. McIntosh et al.
CANCER (2020)
Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
Eduard Roussel et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cytoreductive nephrectomy (CN) in metastatic renal cancer (mRCC): Update on Carmena trial with focus on intermediate IMDC-risk population.
Arnaud Mejean et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib The SURTIME Randomized Clinical Trial
Axel Bex et al.
JAMA ONCOLOGY (2019)
Individualised Indications for Cytoreductive Nephrectomy: Which Criteria Define the Optimal Candidates?
Alessandro Larcher et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
Andrew W. Hahn et al.
EUROPEAN UROLOGY ONCOLOGY (2019)
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio
Kyongsun Pak et al.
JAMA ONCOLOGY (2017)
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations
Laurence Albiges et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study
Nawar Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
Yoram S. Baum et al.
ASIAN JOURNAL OF UROLOGY (2016)
Body mass index and risk of renal cell cancer: A dose-response meta-analysis of published cohort studies
Furan Wang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Vitaly Margulis et al.
EUROPEAN UROLOGY (2013)
Body mass index and survival in patients with renal cell carcinoma: A clinical-based cohort and meta-analysis
Yuni Choi et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy
Umberto Capitanio et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study
Daniel Y. C. Heng et al.
LANCET ONCOLOGY (2013)
Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy
Alexander Kutikov et al.
BJU INTERNATIONAL (2010)
Can We Better Select Patients With Metastatic Renal Cell Carcinoma for Cytoreductive Nephrectomy?
Stephen H. Culp et al.
CANCER (2010)
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Agents: Results From a Large, Multicenter Study
Daniel Y. C. Heng et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed
Phillip M. Pierorazio et al.
BJU INTERNATIONAL (2007)
Cytoreductive nephrectomy in patients with metastatic renal cancer: A combined analysis
RC Flanigan et al.
JOURNAL OF UROLOGY (2004)
Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials - Effect of measurement criteria and other parameters
LH Schwartz et al.
CANCER (2003)
Share Paper
